In the PARADIGM-HF clinical trial, it was shown that sacubitril-valsartan was able to reduce the occurrence of CV deaths or hospitalization resulting from the worsening of CHF by 20% compared to the ACE inhibitor, enalapril. This evidence concerns the gene ACE and congestive heart failure.